
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1580146
This article is part of the Research TopicCommunity Series in Th2-Associated Immunity in The Pathogenesis of Systemic Lupus Erythematosus and Rheumatoid Arthritis: Volume IIView all 5 articles
The final, formatted version of the article will be published soon.
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The objective of this study is to compare the clinical features and survival outcomes of class IV±V lupus nephritis (LN) patients, identify risk factors, and develop an accurate prognostic model. This study enrolled patients diagnosed with class IV±V LN by renal biopsy at Xijing Hospital from December 2013 to June 2023. The composite endpoint of the study was defined as a decline in the estimated glomerular filtration rate (eGFR) by more than 50%, progression to end stage renal disease, or death, whichever came first.ESRD is defined as an eGFR <15ml/min/1.73m2, necessitating the commencement of chronic dialysis (hemodialysis or peritoneal dialysis) or kidney transplantation. We compared the baseline features and survival prognosis between patients with class IV±V LN. The prognostic model was developed using machine learning algorithms and Cox regression. The model's performance was evaluated in terms of discrimination, calibration, and risk classification using the concordance index (C-index), integrated brier score (IBS), net reclassification index (NRI), and integrated discrimination improvement (IDI), respectively. Results: A total of 313 patients were enrolled for this study, including 156 class IV and 157 class IV+V LN. During the median follow-up period of 42.6 (17.0, 83.4) months, 35 (22.4%) class IV and 38 (24.2%) class IV+V LN patients experienced combined events. Class IV and class IV+V patients have similar clinical manifestations, treatment strategies, and long-term prognosis, despite class IV having a higher chronic index (CI) score (P < 0.001). Seven eligible variables (eGFR, CI, age, basophil percentage, red blood cell count, mean arterial blood pressure, and uric acid) were selected to develop the random survival forest (RSF) model. This model demonstrated the best performance with a C-index of 0.771 (0.667, 0.848) and an IBS of 0.144 (0.132, 0.154). The IDI and NRI in the testing set further confirmed that the RSF model exhibited superior risk classification and discrimination capabilities. Conclusion: Class IV±V LN was similar in clinical manifestations, treatment strategies, and longterm prognosis, despite differences in pathological features. The RSF model we established for class IV±V LN patients, incorporating seven risk factors, exhibits superior survival prediction and provides more precise prognostic stratification.
Keywords: Lupus Nephritis, class IV±V, machine learning, risk factor, Prognostic model
Received: 20 Feb 2025; Accepted: 17 Apr 2025.
Copyright: © 2025 Wang, Qin, Xing, Yu, Huang, Yuan, Hui, Han, Xu, Zhao and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jin Zhao, Department of Nephrology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
Shiren Sun, Department of Nephrology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Supplementary Material
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.